Development and Characterization of Self-healing Transdermal Patch of Lidocaine for the Management of Pain
Pain management is a significant challenge due to the side effects associated with commonly prescribed medications like NSAIDs and opioids. Local anesthetics, such as lidocaine, offer an alternative with fewer side effects when formulated in topical patches. Transdermal delivery systems, including heated patches, enhance drug absorption and provide targeted pain relief. This research paper aims to develop and characterize a self-heating transdermal patch of lidocaine for pain management. The drug sample of lidocaine was characterized using UV-visible spectrophotometric analysis, melting point determination, and differential scanning calorimetry. The results confirmed the purity of the drug sample. Pre-formulation studies were conducted to determine the solubility and partition coefficient of lidocaine, as well as drug-excipient interaction studies. The formulation of the lidocaine transdermal patch included the selection of excipients such as solvents, adhesives, solubilizers, and permeation enhancers. The patch was developed in three trial batches, with the final batch prepared using a drug-in-adhesive type approach. The developed patch was evaluated for physical characteristics, solvent residual content, rolling ball test, shear strength, drug crystallization, drug content, and in-vitro permeation. The results of the evaluation showed that the developed lidocaine transdermal patch had the desired physical characteristics, uniform thickness, good folding endurance, and appropriate solvent residual content. It exhibited satisfactory rolling ball test and shear strength. Microscopic examination confirmed the absence of drug crystallization. The drug content of the patch was determined to be within the desired range, and the in-vitro permeation study demonstrated successful drug release through the dialysis membrane. In conclusion, the development and characterization of a self-heating transdermal patch of lidocaine for pain management provide a promising approach for effective and targeted pain relief. The patch formulation demonstrated suitable physical properties, drug content, and permeation characteristics, suggesting its potential as an alternative pain management solution.
2. Finnerup NBJNEJoM. Nonnarcotic methods of pain management. 2019;380(25):2440-8.
3. Świeboda P, Filip R, Prystupa A, Drozd MJP. Assessment of pain: types, mechanism and treatment. 2013;2(7).
4. Verma NK, Panda P, Mishra J, Vishwakarma D, Singh A, Alam GJIJAPIJAP. Advances and development in transdermal drug delivery system—A Review. 2017; 6:49-62.
5. Chien YWJDd, pharmacy i. Development of transdermal drug delivery systems. 1987;13(4-5):589-651.
6. Wokovich AM, Prodduturi S, Doub WH, Hussain AS, Buhse LFJEJoP, Biopharmaceutics. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. 2006; 64(1):1-8.
7. Gaikwad AKJCJoPS. Transdermal drug delivery system: Formulation aspects and evaluation. 2013; 1(1):1-10.
8. Jhawat VC, Saini V, Kamboj S, Maggon NJIJPSRR. Transdermal drug delivery systems: approaches and advancements in drug absorption through skin. 2013; 20 (1):47-56.
9. Sankar V, Johnson DB, Sivan V, Ravich V, Raghuraman S, Velrajan G, et al. Design and evaluation of nifedipine transdermal patches. 2003;65(5):510.
10. Arora P, Mukherjee BJJops. Design, development, physicochemical, and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt. 2002;91(9):2076-89.
11. Cilurzo F, Gennari CG, Minghetti PJEoodd. Adhesive properties: a critical issue in transdermal patch development. 2012; 9(1):33-45.
12. Pastore MN, Kalia YN, Horstmann M, Roberts MSJBjop. Transdermal patches: history, development and pharmacology. 2015; 172(9):2179-209.
13. Patel RP, Patel G, Patel H, Baria AJRJoPDF, Technology. Formulation and evaluation of transdermal patch of aceclofenac. 2009;1(2):108-15.
14. Prajapati ST, Patel CG, Patel CNJISRN. Formulation and evaluation of transdermal patch of repaglinide. 2011;2011.
15. George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. 2000; 157(11):1835-42.
16. Dhiman S, Singh TG, Rehni AKJIJPPS. Transdermal patches: a recent approach to new drug delivery system. 2011; 3(5):26-34.
17. Ren C, Fang L, Ling L, Wang Q, Liu S, Zhao L, et al. Design and in vivo evaluation of an indapamide transdermal patch. 2009; 370(1-2):129-35.
18. Ah Y-C, Choi J-K, Choi Y-K, Ki H-M, Bae J-HJIJoP. A novel transdermal patch incorporating meloxicam: in vitro and in vivo characterization. 2010; 385(1-2):12-9.
19. Gannu R, Vamshi Vishnu Y, Kishan V, Madhusudan Rao YJCDD. Development of nitrendipine transdermal patches: in vitro and ex vivo characterization. 2007; 4(1):69-76.
20. Al Hanbali OA, Khan HMS, Sarfraz M, Arafat M, Ijaz S, Hameed AJAP. Transdermal patches: Design and current approaches to painless drug delivery. 2019; 69(2):197-215.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.